Aptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors

In lab studies, APVO451 and APVO452 helped immune cells kill cancer cells despite conditions that suppress immune activity - offering potential for difficult-to-treat solid tumorsPreclinical work also showed that APVO711 both activated immune cells …